





Microfluidics for pharmaceutical nanoparticle fabrication: the truth and the myth 
Sherif I. Hamdallah1,2, Randa Zoqlam1, Peer Erfle3,4, Mark Blyth5, Alaaldin M. Alkilany. A. 
M.6, Andreas Dietzel3,4, Sheng Qi1 
1 School of Pharmacy, University of East Anglia, Norwich, NR4 7TJ, UK 
2 Department of Pharmaceutics, Faculty of Pharmacy, Alexandria University, Alexandria, 
Egypt 
3Technische Universität Braunschweig, Institut für Mikrotechnik / Institute of 
Microtechnology, Alte Salzdahlumer Str. 203, Geb. 1A, 38124 Braunschweig 
4Technische Universität Braunschweig, Center of Pharmaceutical Engineering, Franz-Liszt-
Str. 35a, 38106 Braunschweig, Germany 
5School of Mathematics, University of East Anglia, Norwich, NR4 7TJ, UK 
6Department of Pharmaceutics & Pharmaceutical Technology, School of Pharmacy, 










Using micro-sized channels to manipulate fluids is the essence of microfluidics which has 
wide applications from analytical chemistry to material science and cell biology research. 
Recently, using microfluidic-based devices for pharmaceutical research, in particular for the 
fabrication of micro- and nano-particles, has emerged as a new area of interest. The particles 
that can be prepared by microfluidic devices can range from micron size droplet-based 
emulsions to nano-sized drug loaded polymeric particles. Microfluidic technology poses 
unique advantages in terms of the high precision of the mixing regimes and control of fluids 
involved in formulation preparation. As a result of this, monodispersity of the particles 
prepared by microfluidics is often recognised as being a particularly advantageous feature in 
comparison to those prepared by conventional large-scale mixing methods. However, there is 
a range of practical drawbacks and challenges of using microfluidics as a direct micron- and 
nano-particle manufacturing method. Technological advances are still required before this 
type of processing can be translated for application by the pharmaceutical industry. This 
review focuses specifically on the application of microfluidics for pharmaceutical solid 
nanoparticle preparation and discusses the theoretical foundation of using the 
nanoprecipitation principle to generate particles and how this is translated into microfluidic 
design and operation.  
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Microfluidics concerns the design and fabrication of miniaturized microscale devices 
containing channels and chambers of different geometry in which fluid mixing can be 
controlled precisely (Nguyen et al., 2013; Ong et al., 2008; Tsui et al., 2013; Whitesides, 
2006). In contrast to macroscale flow systems, where inertial forces play an important role, 
viscous forces dominate in microfluidic devices, and this explains why laminar flow is typical 
in these miniaturized systems (Ahn et al., 2018; Liu et al., 2015; Lu et al., 2016; Riahi et al., 
2015). Microfluidics technology is a multidisciplinary research field that brings together 
technologies and principles from fluid dynamics, physics, biology, microtechnology, material 
science and chemistry. The point of merger of analytical chemistry and biochemistry with 
microelectronics is considered the real birth of microfluidic technology (Tian and Finehout, 
2009). Microfluidics technology has found extensive applications in various areas of science. 
Applications to pharmaceutical technologies include fabricating nanoparticle-based drug 
delivery systems (Damiati et al., 2018; Lu et al., 2016; Martins et al., 2018; Pan et al., 2017; 
Weigl et al., 2003) and performing pre-clinical tests for substances and formulations using 
the so-called “organ-on-chip” systems (Beißner et al., 2016; Bhise et al., 2014; Li and Tian, 
2018). There is a vast number of excellent reviews on both topics (Liu et al., 2018; Martins et 
al., 2018; Probst et al., 2018; Riahi et al., 2015; Valencia et al., 2012).  The emphasis of the 
present review is on discussing the advantages and disadvantages of using microfluidics for 
the fabrication of polymeric nanoparticles and drug nanosuspensions via the 
nanoprecipitation method.  
 
For pharmaceutical applications, the functionality of the nanoparticles is often determined by 
key characteristics such as their shape, size, and surface properties (Ealias and 
Saravanakumar, 2017; Jeevanandam et al., 2018; Pande and Ashok Bhaskarwar, 2016). The 
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desired properties of nanoparticles can be achieved with an appropriate method of 
preparation. There are two approaches for nanoparticle formation, namely the top-down and 
bottom-up approaches (Jeevanandam et al., 2018; Pande and Ashok Bhaskarwar, 2016). Top-
down approaches involve particle size reduction by comminution (usually a high-energy 
process, for example ball milling). Bottom-up techniques are commonly used for the 
synthesis of organic nanoparticles, in which the material (drug and/or polymer) is dissolved 
in an appropriate solvent and then thoroughly mixed with an antisolvent to induce particle 
formation via nucleation, growth and precipitation. This approach builds nanostructured 
materials gradually from molecules or atoms into larger structures of nanometer size through 
a controlled precipitation process (Pande and Ashok Bhaskarwar, 2016). The difference 
between the various methods that follow this approach is the mechanism used to induce the 
phase separation (precipitation) of the required component (Pande and Ashok Bhaskarwar, 
2016). Phase separation can be induced by many factors such as the ambient temperature and 
pH, and by a change in the solubility of the components. Therefore a fuller understanding of 
the phase separation mechanism is key to understanding how to control precipitation and to 
obtaining the desired nanoparticles (Pande and Ashok Bhaskarwar, 2016). 
 
This review has a particular focus on antisolvent based nanoprecipitation using microfluidic 
devices for the fabrication of polymeric and drug nanoparticles. Traditionally, 
nanoprecipitation can be achieved by mixing bulk volumes of the solvent (containing the 
solute) and the antisolvent using conventional mixing methods. The unique advantage of 
microfluidic systems compared to conventional bulk mixing methods is their ability to offer 
precise controllability and tunability of the mixing process (Marre and Jensen, 2010; Martins 
et al., 2018; Su et al., 2007) that, in principle, can be scaled up by parallelized systems (Lim 
et al., 2014a). This review aims first to provide an overview of the results that can be 
5 
 
achieved by using microfluidic mixing in the nanoprecipitation process of either polymeric or 
drug nanoparticles. Second, it aims to assess the pros and cons of using microfluidics in 
nanoprecipitation compared to other conventional bulk mixing methods that have advantages 
in high throughput.  
 
2. The Theory: Nucleation and growth of nanoparticles by nanoprecipitation 
2.1 Thermodynamics of homogeneous nucleation  
Nucleation is the process that precedes the formation of a new phase due to a change in the 
system equilibrium (De Yoreo, 2003; Dimo Kashchiev, 2000; Vekilov, 2010; Xiang Y. Liu, 
2001). It can be induced by a change in the solute concentration to exceed the equilibrium 
solubility (supersaturation) or by a drop of the system temperature below the phase 
transformation point (supercooling). Supercooled or supersaturated systems possess high 
Gibbs free energy (∆G), which gets reduced by the formation of molecular or atomic clusters 
(Dimo Kashchiev, 2000). Part of these clusters form the nuclei and exist in equilibrium with 
the dissolved parent phase. Only super-nuclei, which are nuclei that reach the critical size, 
can proceed to grow, while nuclei that are below the critical dimensions dissociate in the 
dissolved parent phase. Nucleation that occurs spontaneously is known as homogeneous 
nucleation. It describes systems where nuclei are formed uniformly throughout the system. 
However, nucleation that can be induced by the presence of foreign entities that form a 
nucleating surface such as impurities, dust or the rough surfaces of the container is known as 
heterogeneous nucleation (Sear, 2006; Thanh et al., 2014). In the most reported cases of using 
the nanoprecipitation method to produce nanoparticles, the underpinning mechanism is 
dominated by homogeneous nucleation. Therefore, in this review we exclusively focus the 
discussion on the factors controlling the homogeneous nucleation rate and their subsequent 




The nucleation process is associated with a change in the total Gibbs free energy (∆G) of the 
system, which can be interpreted as the sum of the excess surface free energy change per unit 
area (∆µs) and the excess volume free energy change (∆Gv) per unit volume (∆µv), as shown 
in Eq. 1 (Ealias and Saravanakumar, 2017; Polte, 2015; Thanh et al., 2014; Liu, 2001). 
Assuming the formation of a spherical nucleus (r as the radius of the spherical nucleus), ∆µs, 
∆µv, surface energy (𝛾) and the total free energy change can be rearranged as shown in Eq. 
2-4 (Ealias and Saravanakumar, 2017; Polte, 2015; Thanh et al., 2014; Liu, 2001).  
∆𝐺 =  ∆µ𝑣 +  ∆µ𝑠                                                                       Eq. 1 
∆µ𝑠 = 4𝜋𝑟2 𝛾                                                                               Eq. 2 




) 𝜋𝑟3 ∆𝐺𝑣 + 4𝜋𝑟2 𝛾                                                           Eq. 4 
Spontaneous nucleation is driven by the reduction of the overall Gibbs free energy of a 
supersaturated solution due to the formation of a solid phase (the precipitated particles which 
provide the excess volume and surface within the system) and the maintenance of an 
equilibrium concentration in the solution (Cao and Wang, 2011). This reduction is 
attributable to the negative value of ∆Gv, which is dependent on the solute concentration, 
emphasizing that supersaturation is the main driving force for nucleation as illustrated in Eq. 
5 (Dimo Kashchiev, 2000), where ∆Gv is the free energy of the bulk crystal, k is Boltzmann’s 
constant, T is the absolute temperature (in Kelvin), C is the solute concentration, Co is the 
solubility, Ω is the atomic volume and σ is the degree of supersaturation that can be defined 
as (C-Co)/Co. When the system is undersaturated (σ=0) and ∆Gv=0, nucleation cannot take 
place. However, when the system is supersaturated (i.e. C>Co), ∆Gv is negative and 
spontaneous nucleation predominates (Figure 1).  
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Figure 1. Schematic illustration of the total free energy change as a function of nucleus radius 
(reprinted with permission from (Thanh et al., 2014)). 
 
The reduction in the total Gibbs free energy is compensated by an increase in the surface 
energy by an amount equal to the interfacial tension for each unit area of the forming 
interface. Consequently, the net free energy of nucleation can be interpreted as the sum of the 
surface free energy and the volume free energy as illustrated by Eq. 4 (Ealias and 
Saravanakumar, 2017; Polte, 2015; Thanh et al., 2014; Liu, 2001). The overall free energy 
change increases with the size increase until the nucleus grows to the maximum size defined 
as the critical size (r*) (Figure 1). After this, the net free energy undergoes a gradual decrease 
for any further increase in the nucleus size (Polte, 2015; Thanh et al., 2014). This is known as 
the LaMer mechanism, which states that nucleation and growth of nanoparticles occur in 
three stages (Thanh et al., 2014). The first stage is characterized by an increase in the solute 
concentration to reach the minimum solute concentration needed to induce nucleation 
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(referred as Cmin) (Thanh et al., 2014). This is followed by the next stage, where “burst 
nucleation” takes place leading to a significant reduction in the solute concentration, which 
consequently reduces the nucleation rate to zero (Thanh et al., 2014). The last stage is known 
to be a diffusion-controlled growth process. The minimum size needed for the particle to 
proceed to the growth phase is known as the critical radius, r* (Thanh et al., 2014). Two 
important terms that can be derived from Eq. 4, which are the critical radius (r*) and critical 
∆G (∆G*), are expressed in Eq. 6 and Eq.7 (Polte, 2015; Thanh et al., 2014; Xiang Y. Liu, 
2001). 
 𝑟∗  =  −2 𝛾/ ∆𝐺𝑣                                                                     Eq. 6 
 
Critical ∆G (∆G*) illustrated in Figure 1 is defined as the energy barrier that must be 




                                                                    Eq. 7 
 
In conclusion, these equations explain that the critical size of the nucleus and the critical 
energy barrier can be reduced by either increasing the free energy of the bulk crystal (∆Gv) or 
by reducing the surface free energy (γ). An increase in the supersaturation can increase the 
(∆Gv) leading to an overall decrease in the critical energy barrier. Also, a decrease in the 
system temperature can lead to an overall decrease in r* and ∆G*. 
 
2.2 Rate of nucleation  
The rate of nucleation per unit volume can be defined as the number of nuclei that can form 
in a solution per unit time. It is considered as one of the most important factors that determine 
the properties of the nanoparticles (Dimo Kashchiev, 2000; Sinha et al., 2013; Vekilov, 
2010). A rapid and uniform nucleation process forms smaller particles with a narrow size 
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distribution (Sinha et al., 2013; Vekilov, 2010). This can be explained by the spontaneous 
formation of many crystals, which causes a significant and a rapid drop in the supersaturation 
level. As a result of the rapid reduction of the supersaturation level, the nucleation process is 
terminated and the growth process starts, where most of the particles grow to the same size. 
However, slow nucleation causes a slow drop in the supersaturation level, which allows the 
nucleation to occur over a longer period of time (Sinha et al., 2013; Vekilov, 2010). This can 
lead to a broad size distribution for the nanoparticles. Therefore the size of the nanoparticles 
can be controlled by controlling the rate of nucleation (𝑑𝑁/𝑑𝑡) (Sinha et al., 2013).  The 
Arrhenius equation (Eq. 8) describes all the factors that can have a significant influence on 
the rate of nucleation (𝑑𝑁/𝑑𝑡). These are supersaturation (S), surface free energy (𝛾) and the 
temperature (T). A is a pre-exponential factor (Thanh et al., 2014). A supersaturated system 
possesses a low critical energy barrier and has a high nucleation rate. Supersaturation was 
found to be the factor with the largest effect on the nucleation rate, as shown in Figure 2 
(Thanh et al., 2014). 
𝑑 𝑁
𝑑𝑡
=  𝐴 exp (16𝜋 γ3𝑣2/ 3 𝑘3𝑇3 (lnS) 2)                                           Eq. 8    
 
 
Figure 2. The effect of the a) supersaturation, b) temperature, and c) surface free energy on 




In the antisolvent nanoprecipitation process, the mixing of the solvent and the antisolvent 
pose a significant effect on the uniformity and the rate of nucleation, which consequently 
control the size and surface properties of the nanoparticles (Sinha et al., 2013). An efficient 
and uniform mixing ensures a uniform supersaturation throughout the solution (Sinha et al., 
2013). Consequently, this induces a uniform nucleation, which results in the formation of 
smaller particles with a narrower size distribution in comparison to non-uniform mixing 
(Figure 3) (Dimo Kashchiev, 2000; Sinha et al., 2013). These factors are discussed more in 
detail later in section 3.     
 
Figure 3. Illustration of the effect of the mixing efficiency on the final particle sizes 
(reprinted with permission from (Sinha et al., 2013)). 
 
2.3 Classical growth theory 
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A rapid and uniform nucleation is a prerequisite for fabricating nanoparticles with small 
particle size and narrow size distribution (Sinha et al., 2013). However, the size distribution 
can be affected by both the nucleation process and the kinetics of the growth process (Cao 
and Wang, 2011; Sinha et al., 2013). Nucleation and growth occur simultaneously when the 
solute concentration exceeds Cmin (Sinha et al., 2013). However, the rate at which each 
process proceeds can be different (Cao and Wang, 2011). In the case of homogenous 
nucleation, rapid nucleation ensures that all nuclei form simultaneously. These nuclei 
undergo a similar growth process over time, which lead to the production of monodisperse 
nanoparticles. However, this does not apply when the nucleation occurs over a long period of 
time (Cao and Wang, 2011).  
 
The growth process starts with the formation of the reactants named as “growth species”. The 
growth species diffuse and are adsorbed onto the surface of the nucleus, leading to a growth 
in size (Cao and Wang, 2011). The continuous growth of the particle size can be controlled 
by either diffusion or surface mechanisms (Cao and Wang, 2011). Each one of these 
processes can lead to particle population with a different size distribution (Cao and Wang, 
2011).   
 
2.3.1. Diffusion-controlled growth 
The nucleation process stops when the solute concentration drops below Cmin, and the growth 
of the nanoparticles proceeds as illustrated in Figure 4. If the growth of the nanoparticles is 
controlled by the diffusion of the monomers from the bulk solution to the solid surface of the 
nuclei, the growth will result in the formation of monosized nanoparticles (Cao and Wang, 
2011; Sinha et al., 2013). This can be described by Eq. 9, where r is the radius of the particle, 
D is the diffusion coefficient of the solute molecule, C is the concentration of the monomers 
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in the bulk, Cs is the concentration of the monomers at the solid liquid interface and Vm is the 
molar volume of the nucleus (Sinha et al., 2013). By solving the equation and assuming that 
ro is the initial radius of the nucleus, the equation can be rearranged to Eq. 10. As KD= 2D (C-






                                                                                       Eq. 9 
       𝑟2 =  𝐾𝐷𝑡 +   𝑟𝑜
2                                                                                     Eq. 10 
 
Assuming that the initial radius difference for two particles is δro, the radius difference (δr) 
decreases as time increases or the particles grow bigger as illustrated in Eq. 11 (Cao and 
Wang, 2011). By combining Eq. 10 and 11 into Eq. 12, it can be proved that the radius 
difference decreases over time. This explains how diffusion-controlled growth produces 
particles with a narrow size distribution (Cao and Wang, 2011; Sinha et al., 2013).  
𝛿𝑟 =  𝑟𝑜  𝛿𝑟𝑜/𝑟                                                                                                Eq. 11       
𝛿𝑟 =  𝑟𝑜  𝛿𝑟𝑜  /(𝐾𝐷𝑡 + 𝑟𝑜
2 )1/2                                                               Eq. 12 
 
There are some suggested practical methods to achieve growth driven by diffusion, which is 
desirable for making monodisperse nanoparticles. These include increasing the viscosity of 
the bulk solution or introducing a layer on the surface of the nanoparticles as a barrier for the 
monomer’s diffusion (Cao and Wang, 2011). These methods ensure that the diffusion is the 




Figure 4. Illustration of the temperature and solute concentration effects on nucleation and 
growth processes (reprinted with permission from (Sinha et al., 2013)). 
 
2.3.2. Surface-controlled growth 
The growth is dominated by surface processes when the diffusion of the monomers from the 
bulk solution to the surface of the particles occurs rapidly (Cao and Wang, 2011). Two main 
mechanisms drive surface-controlled growth. These are mononuclear growth and poly-
nuclear growth (Cao and Wang, 2011). In monolayer growth the particles have sufficient 
time to grow because growth occurs sequentially layer-by-layer. In this case the growth rate 
is proportional to a particle’s surface area (Cao and Wang, 2011). This means that 
mononuclear growth is not suitable for making mono-sized nanoparticles, as is illustrated in 
Figure 5. However, in poly-nuclear growth the surface concentration of the reactant is very 
high, and the process occurs sufficiently rapidly for the second layer to begin forming before 
the first layer is completed. In this case the growth rate is relatively uniform and depends 
only on temperature. Therefore, poly-nuclear growth is considered to be favourable for 




Whether the growth process is diffusion-controlled or surface-controlled is indicated by the 
size of the Damköhler number (Da) (Sinha et al., 2013). This dimensionless number 
represents the ratio of tmixing to tprecipitation, where tmixing is the time required to achieve complete 
homogenous mixing and tprecipitation is the time required to allow the drug concentration 
reaching the critical nucleation concentration (Cn) and initiating the formation of the nuclei. If 
Da is much less than 1, the reaction is controlled by diffusion (Sinha et al., 2013). If Da is 
much larger than 1, the reaction is surface controlled. If Da is on the order of 1 both surface 
processes and diffusion are important.  
 
Figure 5. Schematic illustration of the changes of the radius difference between two particles 
(r) during the growth process as functions of (A) growth time and (B) particle size for all 





3. Experimental considerations 
3.1. General factors affecting nanoprecipitation process 
The theoretical background described above forms the fundamental principle of nanoparticles 
formation by nanoprecipitation method. Experimentally, the precipitation process is regulated 
by several parameters and processes as illustrated by Figure 6. These variables are 
interdependent; therefore, it is difficult to discuss them completely in isolation.  
 
Figure 6. Fish-bone diagram depicting various interdependent factors influencing the quality 
attributes of precipitation process (reprinted with permission from (Sinha et al., 2013)). 
 
3.1.1 Degree of supersaturation 
Degree of supersaturation is the ratio between drug concentration in the binary mixture of 
solvent and aqueous-based antisolvent after mixing and its equilibrium solubility in that 
mixture. Supersaturation, in most cases, is the driving force of the precipitation process 
(Haberkorn et al., 2003). The degree of supersaturation is expressed by Eq. 13, in which C is 
the drug concentration in the solvent and CEq is the saturated drug concentration under 
equilibrium in the binary mixture. In principle, increasing the degree of supersaturation 
increases the nucleation rate and subsequently decreases the size of the precipitated particles.  
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𝐷𝑒𝑔𝑟𝑒𝑒 𝑜𝑓 𝑠𝑢𝑝𝑒𝑟𝑠𝑎𝑡𝑢𝑟𝑎𝑡𝑖𝑜𝑛 =
𝐶
𝐶𝐸𝑞
                                      Eq. 13 
 
As illustrated in Figure 7, in the case of low degree of supersaturation, the system will spend 
limited time in the supersaturation phase (where the nucleation happens homogenously 
spontaneously with minimum crystals growth) and much longer time passing through the 
metastable zone (where the crystals growth predominates over the nucleation) which 
ultimately will produce larger poly-dispersed particles in comparison to those produced at a 
higher degree of supersaturation. However, high degree of supersaturation shortens the 
tprecipitation (defining the time required to start the precipitation) and allows the precipitation to 
start before homogenous mixing can be reached (Da < 1). This results in the fabrication of 
large poly-dispersed particles unless a very efficient mixing tool/process is used (Tao et al., 
2019). 
 
Increasing the degree of supersaturation of either a drug or a polymer could be achieved by 
manipulating the antisolvent phase (increasing the volume or decreasing mixing temperature) 
or the solvent phase (increasing the volume or drug/polymer concentration). Such 
manipulation may also have a subordinate effect on the precipitation process. For instance, 
increasing the volume of the antisolvent decreases the overall drug/polymer concentration, 
which lowers the collision rate and reduces the probability of nanoparticles aggregation. On 
the contrary, increasing the volume of solvent phase boosts the Ostwald ripening effect due to 




Figure 7. The effect of the degree of supersaturation on the process of precipitation (reprinted 
with permission from (Tao et al., 2019)). 
 
3.1.2. The mixing process of solvent and antisolvent  
The mixing process of the solvent and the antisolvent is considered to be the most crucial step 
for producing nanoparticles with small particle size and narrow size distribution. Generally, a 
uniform mixing is a prerequisite to achieve a uniform supersaturation throughout the bulk 
solution, which triggers a uniform nucleation. The Ostwald ripening effect is neglected when 
monodisperse nanoparticles are formed, which enhances the physical stability of the resultant 
particles (Thorat and Dalvi, 2012) (Figure 7). 
 
The uniformity of the mixing of the solvent and antisolvent is heavily dependent on the mode 
of flow when the mixing proceeds. In turbulent flow, which occurs in conventional mixing 
methods such as magnetic stirrers, the mixing process can be subdivided into three mixing 
scales: macro-, meso-, and micromixing. Macro-mixing encompasses the macroscopic flow 
processes on the decimetre scale, while meso-mixing describes mixing processes on the 
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millimetre scale, which are based on turbulent vortex breakdown. Micro-mixing represents 
the mixing on the smallest scales of motion (known as Kolmogrov scale) which in most cases 
relies on molecular diffusion as a driving force for mass transfer (Mohammad et al., 2008). 
 
Once the mixing is completed, the whole precipitation process could be chronologically 
divided into three distinct time scales; the first is the precipitation time, tprecipitation, also known 
as the nucleation induction time. At tprecipitation the drug concentration reaches the critical 
nucleation concentration (Cn), which initiates the formation of the nuclei. The second phase is 
the growth time, tG, during which the precipitated nuclei start to grow by further 
accumulation of dissolved drug/polymer molecules on the newly precipitated nuclei, as 
detailed in section 2.3. Finally, during the aggregation phase, the grown, precipitated nuclei 
collide and aggregate (Martínez Rivas et al., 2017) (Figure 7). 
 
The homogeneity of the precipitation process is indicated by the size of Da. Ideally Da 
should be below 1 in order to achieve a homogenous precipitation and produce small and 
uniform nanoparticles. This ensures a complete uniform distribution of the solvent phase 
within the antisolvent phase before the precipitation step starts. This could be achieved by 
either lowering tmixing (through enhancing the mixing efficiency) or increasing tprecipitation 
(through increasing the viscosity to reduce molecular mobility or using stabilizers) (Chan and 
Kwok, 2011). 
 
Multitudinous methods/tools with different mixing efficiencies have been assessed to be used 
to perform the mixing step. These include simple stirring using magnetic stirrers (Freag et al., 
2013; Shariare et al., 2019) , static mixers (Dong et al., 2010) (in which solvent and 
antisolvent fluids are pumped at high rates (litres per min) through a small nozzles to hit 
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mixing elements (such as blades) to induce turbulent mixing), and the recently introduced 
techniques that uses microfluidics including micromixer chips, and high energy input jet 
stream mixers (microfluidizers) (Salazar et al., 2014). Recently, the use of microfluidic 
systems of different channel and mixing junction geometries has been introduced to provide a 
controlled, tuneable and continuous scalable mean for efficient fluid mixing and 
nanoparticles production. This is further discussed in section 3.2. 
 
Simple mixing, which is performed by conventional mixing with active stirrers, is often not 
sufficient to produce small monodisperse drug/polymer nanoparticles in moderate 
concentrations of the drug/polymer. Thus high energy processes are required to aid in the 
development of small monodisperse nanoparticles (Freag et al., 2013; Zhang et al., 2006). 
Examples of such high energy processes include ultrasonication (Dhumal et al., 2008; Gajera 
et al., 2019), high pressure homogenization (Salazar et al., 2014), and high shear 
homogenization (Karakucuk et al., 2019; Yu et al., 2018). The small particle size obtained by 
these methods is often a result of the improved mixing efficiency due to cavitation (in the 
case of ultrasonication) and turbulent currents which minimise particle growth after 
nanoparticles precipitation (Sinha et al., 2013). During these high-energy processes, the 
drug/polymer is firstly precipitated after the addition of the antisolvent phase.  
 
In the case of drug molecules being the solute, unstable fragile form of nanoparticles is firstly 
obtained in the initial stage of precipitation, which may be amorphous, semi-crystalline or 
super-cooled liquid form. This unstable form is then transformed to a more stable crystalline 
drug particle in the presence of high energy during annealing. Throughout the annealing 
process, the highly energetic thermodynamically unstable form of the precipitated particles is 
converted into a form of lower energy and higher stability via single or repeated application 
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of energy (from mechanical stress or the generated heat), followed by thermal relaxation 
(Sinha et al., 2013). 
 
3.1.3. Solute (drug /polymer) concentration in solvent phase 
Solute (which could be either drug or polymer in the cases of making drug or polymeric 
nanoparticles) concentration in solvent phase is another key factor to manipulate the degree 
of supersaturation. As illustrated in Figure 4, Increasing solute concentration in solvent phase 
will increase the total content of the solute in the binary mixture of the solvent and anti-
solvent, thus increases the degree of supersaturation causing rapid and uniform nucleation 
and producing small nanoparticles (Dalvi and Dave, 2009). However, when the solute 
concentration is too high (above the optimum solute concentration in Figure 8), there is a 
potential risk for increasing the number of nuclei and their collisions that promote particle 
growth and aggregation. Therefore, the benefit of increasing solute concentration for 
producing small and uniform nanoparticles is concentration dependent (Gajera et al., 2019), 
as demonstrated in Figure 8. This was evaluated by many studies that reported a direct 
increase in the particles size with increasing the polymer concentration (Chorny et al., 2002; 
Nehilla et al., 2008; Seremeta et al., 2013). In addition, the drug solubility in the solvent plays 
a crucial role in determining the degree of supersaturation and the volume of solvent 
required. It, in turn, affects the stability of the formed nanoparticles due to the Ostwald 
ripening effect of the residual solvent in case of using a large volume of the solvent (Gajera et 





Figure 8. The effect of solute concentration in solvent phase on the particle size of the 
precipitated particles. 
 
3.1.4. The volume ratio between the solvent and the antisolvent (S-AS ratio) 
The degree of supersaturation of the solute (drug/ polymer) can also be manipulated by 
varying the solvent/antisolvent volume ratio (S-AS ratio). As shown in Eq. 13, with keeping 
the same solute (drug/polymer) content, increasing S-AS ratio will decrease the degree of 
supersaturation through increasing the solute equilibrium saturated solubility in the binary 
mixture (Kakran et al., 2012; Wang et al., 2007). Furthermore, the high solvent content will 
induce particle growth due to Ostwald ripening after particle precipitation (Gajera et al., 
2019; Verma et al., 2011). Moreover, selecting a solvent that has a good solute dissolving 
capacity is prominent to minimize its volume and ease its removal after the precipitation step 
has been achieved. Different findings have been reported by several studies. For example, 
Budhian et al. reported a decrease in particle size with an increase in drug loading efficiency 
when the solvent volume is decreased (Budhian et al., 2007). This was attributed to the short 
solvent evaporation time, which allows the particles to transfer from the liquid state to the 
locked state rapidly. However, a contradictory finding was reported by Limayem Blouza et 
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al.. They found that the S-AS volume ratio was decreased by increasing the aqueous phase 
volume (Limayem Blouza et al., 2006; Nagy et al., 2019). The size of the nanoparticles was 
found to increase from 320 ± 12 nm to 536 ± 14 nm, with a drop in the drug encapsulation 
efficiency from 96.21% to 75.93%, by increasing the water (as the antisolvent) volume from 
50 ml to 100 ml respectively (Limayem Blouza et al., 2006). This suggests that the properties 
of the nanoparticles can be tuned not only by varying the A-AS ratio but also through the 
means by how it is changed.  
 
3.1.5. Type and concentration of the stabilizer 
The choice of the type and the concentration of the used stabilizer are crucial to assure good 
stabilization of the nanoparticle surfaces against growing and aggregation. A wide variety of 
stabilizers have been used, some being polymeric (non-ionic, linear, hydrophobic or 
amphiphilic), while others being surfactants (ionic or non-ionic) (Van Eerdenbrugh et al., 
2009). The selection of an effective stabilizer should be based on its affinity to be adsorbed 
on the particles’ surfaces. The higher the affinity of stabilizer to drug/polymer, the faster it 
adsorbs and occupies the particle surface; hence smaller particles can be produced. The 
adsorption of the stabilizers (that have surface activity) can decrease the surface free energy 
of the new-born nuclei and lower the tendency of these nuclei to grow or aggregate. In 
addition, some stabilizers stabilize the formed particles either sterically (due to long 
polymeric chains) or statically (due to its charge) to prevent their aggregation during storage. 
In some cases, blends of both steric and static stabilizers are used to provide the most optimal 
stabilization effect (Verma et al., 2011). 
 
The appropriate stabilizer concentration is considered as another vital parameter that is 
interdependent on the nature of the stabilizers and the precipitated solute. Surfactants and 
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polymeric stabilizers possess different mechanisms for nanoparticles stabilization. Increasing 
the surfactants concentration increases the adsorbed fraction of molecules onto the particles’ 
surfaces. This improves the colloidal stability of the nanoparticles. However, there is a 
concentration limit. If the surfactants concentration exceeded the (critical micellar 
concentration), an Ostwald ripening effect can be promoted due to micelles formation. 
Similarly, If the used polymeric stabilizer concentration exceeds the critical flocculation 
concentration (CFC), the polymeric chains start to flocculate and get entangled together 
which promote aggregation and size enlargement (Thorat and Dalvi, 2012). The influence of 
the used stabilizer and its concentration have been widely investigated, yet seemed 
contradictory results were reported.  This emphasizes the effect of the stabilizer being highly 
system dependent and even slight difference in material and processing parameters could lead 
to the deviation of results. For example, while Dong and Feng (2004) reported no significant 
change in the MPEG-PLA nanoparticle size when Pluronic F68 concentration was increased 
(Dong and Feng, 2004), Zweers et al. reported a significant increase in particle size when 
high PVA concentrations were used (Zweers et al., 2003), and Allemann et al. reported a 
continuous decrease in particle size with increasing PVA concentrations (Allémann et al., 
1992). These seemingly contradictory results were systemically analysed by other research 
groups (Lamprecht and Arica, 2005; Nagy et al., 2019). They proposed that the size of the 
resultant nanoparticles could be affected by two competing effects. These are the enhanced 
interfacial stability achieved by the higher PVA concentration (which promotes size 
reduction) and the increased viscosity of the aqueous phase (which reduces the mixing 
efficiency leading to a larger size population of nanoparticles). The dominant factor is 
determined by the system and the processing parameters (Nagy et al., 2019), which reinforces 





3.1.6. Solvent and antisolvent miscibility 
Most of the precipitation processes use an organismic solvent phase to mix with an aqueous-
based antisolvent phase. The miscibility of the solvent with the aqueous-based antisolvent is 
one of the critical factors when choosing the solvent systems, as it is expected to affect the 
mixing step and the solute diffusion into the antisolvent phase. Consequently, this affects the 
homogeneity of the nucleation step and the mean particle size of the precipitated 
nanoparticles. Cheng and co-workers studied the effect of using a range of solvents with 
different water miscibility on the particle size of the produced PLGA NPs (Cheng et al., 
2007). It was found that the solvents with high miscibility with water (e.g. DMF, dimethyl 
formamide) led to the production of smaller NPs in comparison to that produced by solvents 
of lower water miscibility (e.g. THF, Tetrahydrofuran). However, Guhagarkar and co-
workers reported a significant decrease in nanoparticles size when a mixture of THF and 
acetone was used as the solvent phase, explained by the rapid diffusion of the acetone into the 
aqueous antisolvent phase favouring the formation of smaller nanoparticles (Guhagarkar et 
al., 2009; Nagy et al., 2019). 
 
3.1.7. Other factors 
Some other factors impose a contributing effect in controlling the particles size distribution 
and the physicochemical properties of the produced nanoparticles. For instance, reducing the 
temperature of antisolvent was reported to decrease the particle size and narrow the particle 
size distribution (Xia et al., 2010). That could be attributed to the reduction in the equilibrium 
solubility of the solute in the binary mixture that in turn increases the degree of 
supersaturation. Moreover, lowering the temperature increases the system viscosity and 
decreases the particles movement, which decreases the particles growth and collision rates 
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giving more time to the stabilizers to anchor on the particles’ surfaces and preventing their 
aggregation (Dalvi and Dave, 2009; Zhang et al., 2009). It also has been reported that the 
nature of both solvent and antisolvent is able to affect the crystallinity and polymorphic form 
of the produced nanoparticles (Zhang et al., 2006). 
 
3.2 Microfluidic systems as a tuneable tool for efficient mixing 
Recently, the use of microfluidic systems has been increasingly discussed as a means of 
efficient tuneable mixing which is vitally important for producing small nanoparticles with 
narrow size distribution. The tuneability of the particle size can be well controlled by 
systemic screening of the parameters used for the micro-mixing process used in microfluidic 
methods (Dietzel, 2016; Feng et al., 2016; Hessel et al., 2005; Riahi et al., 2015; Sanjay et al., 
2018). The micro-mixing process can be categorized as either active or passive mixing. 
Active mixing in a microchip is tightly controlled by the external energy input, or by 
ultrasonication (Yang et al., 2001) or via an electrokinetic instability (Oddy et al., 2001). In 
passive mixing, the geometry of the microchip is designed to promote mixing within the flow 
without external influence (Hessel et al., 2005; Suh and Kang, 2010). Since passive mixing 
depends only on the microchannel geometry and the imposed flow conditions at the inlet, it is 
readily amendable to downscaling. Furthermore it is the most commonly discussed technique 
for the microfluidic manufacture of nanoparticles. For these reasons we focus the present 
discussion on passive mixing.  
 
Passive mixing is strongly influenced by the prevailing flow within the microchannel. The 
flow is strongly affected by the viscosity and density of the fluid, by the geometry of the 
microchip, and by the surface properties of the channel walls. Typical flow regimes are 
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characterised by the dimensionless Reynolds number, which expresses the ratio between fluid 







                            Eq. 14 
Here V is a typical speed that is representative of the flow, d is a characteristic length (for 
example this might be the channel diameter in the case of a linear bath configuration), and ρ 
and µ are the density and dynamic viscosity of the fluid respectively. Roughly speaking the 
flow is laminar if Re is small and turbulent if Re is large (Bally et al., 2012; Liu et al., 2015; 
Marre and Jensen, 2010). Since the channel diameter d is on the order of micrometres, the 
Reynolds number is typically small and laminar flow is expected (Dietzel, 2016; Martins et 
al., 2018; Van Der Woerd et al., 2003; Weigl et al., 2003). Laminar flow is smooth with well-
ordered streamlines; in contrast turbulent flow is highly irregular and is characterised by 
small-scale flow structures and by rapid and chaotic fluctuations. Microfluidic systems often 
operate at Reynolds numbers below 1, wherein viscous forces dominate over inertial effects 
in a regime known as creeping flow or Stokes flow. However, specialized high-pressure 
microfluidic systems can also provide turbulent mixing conditions: examples include 
confined impinging jets mixers (CIJM), multi-inlet vortex mixers (MIVM) (Richter et al., 
2013) and high pressure homogenization devices (microfluidizers) made from steel (Ebert et 
al., 2017). 
 
Mass transfer is crucial for mixing within microchannels. Mass transfer occurs either by 
molecular diffusion, whereby molecules migrate across the interface separating the different 
fluid phases to be mixed, or by advection, whereby mass is carried directly by the prevailing 
fluid flow. The relative contribution to the mass transport of both of these mechanisms can be 







                        Eq. 15 
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Given the small channel diameters involved in microfluidic systems (d is measured in 
micrometres), Pe is typically small and diffusion provides the principal mechanism for mass 
transfer (Enrica Chiesa et al., 2018). 
 
3.2.1 Laminar flow microchips 
Laminar flow microchips (low Re) represent the majority of reported microfluidic systems. 
Typically, they are made of polydimethylsiloxane (PDMS) and/or glass and they contain 
channels with typical diameters in the micrometre range (e.g. 100 µm to 500 µm) (Figure 9). 
Typical flow rates in these systems are moderate and do not exceed 3 ml/min (high flow rates 
would generate large pressures and cause PDMS chips to detach from the supporting glass 
slide). Usually the Peclet number Pe is less than 1 so that molecular diffusion provides the 
main means of the mass transfer in the microchip. This type of microfluidic systems (glass or 
PDMS microchips) has been widely used to produce both drug nanosuspensions (Amani et 
al., 2014; Panagiotou et al., 2009; Rahimi et al., 2017; Schianti et al., 2011) and polymeric 
nanoparticles (Donno et al., 2017; Karnik et al., 2008).  
 
Figure 9. Laminar flow microchips made of (a) glass and (b) PDMS. (reprinted with 
permission from (Kimura et al., 2016) and (Feng et al., 2015), respectively) 
 
3.2.2. Turbulent flow high-pressure devices for nanoparticle generation  
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These devices are made mainly from metal (aluminium or steel) to withstand high-pressure 
accompanying high flow rates (commonly range from 40 to 120 ml/min) of the fluids. These 
systems such as confined impinging jets mixer (CIJM), and multi-inlet vortex mixer (MIVM) 
(shown in Figure 10) use the same concepts of the precipitation process, but often in this 
context are referred as “flash nanoprecipitation” (Saad and Prud’Homme, 2016; Tao et al., 
2019). These devices depend on pumping the two liquids at high speeds to hit each other at 
certain angles which induce the turbulent mixing. The mass transport in such devices is 
dominated by advective processes. 
 
Figure 10. Schematic illustrations of (a) confined imping jet mixer (CIJM) and (b) multi-inlet 
vortex mixer (MIVM) (reprinted with permission from (Tao et al., 2019)). 
 
3.2.3. Accelerating mixing in microfluidic laminar flow microchips 
As was noted above, the flow in laminar flow microchips is smooth and regular and mixing 
cannot rely on turbulent flow processes. Given the small Peclet numbers involved, mass 
transfer tends to be dominated by diffusion. However, molecular diffusion is very slow: 
diffusive transport over a distance L occurs over a timescale on the order of L2/D, where D is 
the diffusivity of the substance being transported. Since D is typically very small, the 
29 
 
diffusion timescale over reasonable distances (here on the order of 100 µm) may be 
significant. Therefore the main objective when designing a micromixer is to limit the distance 
over which the solvent must diffuse. A general principle is to enlarge the contact area 
between the solvent and the antisolvent by stretching, splitting, folding or breaking up the 
solutions using disturbed flow that is induced by suitable microstructures within the channels. 
This creates thinner fluid layers and hence shorter distances for the solvent to diffuse across 
into the anti-solvent. Consequently this accelerates the mixing process and creates a 
preferential environment for a homogeneous precipitation of nanoparticles. In this context 
different types of mixers have been reported to be successful for producing nanoparticles 
(Dietzel, 2016). 
• Lamination: parallel or sequential  
• Segmentation: sequential or parallel 
• Chaotic Advection 
• Multi-phase flow 
Parallel lamination mixers divide the different solutions to be mixed into a number (n) of sub-
streams which are then merged co-currently (Figure 11a). This requires minimal diffusion 
distances between the solutions and shortens the mixing time by a factor of n² in comparison 
to performing the passive mixing with a single channel. Sequential lamination mixers are 
made of a sequence of repeating transformation structures in each of which the solutions are 
divided into two sub-streams before being subsequently recombined (Figure 11b). Each 
split-and-recombine arrangement produces a doubling of the number of sub-streams. A fast 
reduction of the diffusion distance is achieved and with n repetitions the mixing time reduces 





Figure 11. a) Schematic diagram illustrating parallel lamination of two fluids (solvent and 
anti-solvent) for passive mixing in microchannels. The grey lines represent sidewalls of 
microchannels, which are at a different height than the other; b) Schematic illustrating 
sequential lamination that shows a split and rejoin of the solvent and anti-solvent flowing 
through the microchannel. Several of these elements can be arranged in series to potentiate 
the effect. Each step of split and rejoin is also illustrated as cross-section view.  
 
In sequential segmentation solvent and anti-solvent are injected into the main channel in an 
alternating periodic sequence (Figure 12a). In this process, the solutions are mixed via axial 
dispersion which can accelerate mixing by orders of magnitude (Nguyen, 2011; Nguyen and 
Huang, 2006). The size of the segments is important for determining the speed of mixing, 
which is also influenced by a periodic pressure pulsation at the inlet. Parallel segmentation 
requires an array of nozzles, which inject the solvent into the main channel carrying the anti-
solvent. The size of the individual nozzles and the velocity ratio of the inflowing solvent to 
the anti-solvent determine the surface area of the injected micro streams. Another approach is 
given by the integration of repetitive geometric changes or structural elements in the channel 
which leads to so-called chaotic advection (Figure 12b). It redirects the laminar flow into 
transversal paths by shear fields. The changes in direction of the flow lead to a permanent 
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stretching, folding and twisting of the individual liquid layers during their passage through 
the channel. The strength of the shear forces on the flow is strongly dependent on the 
Reynolds number and on the structural elements within the channel. Such micromixers work 
efficiently only in a certain operational window: the shear forces can be too low if the 
Reynolds numbers are low, but if the Reynolds numbers are too high the structures lose their 
effect or unwanted secondary flows can occur. Micromixers with chaotic advection can 
therefore be classified according to three different flow ranges in which they perform 




Figure 12. a) Schematic illustrating sequential segmentation. Segmentation is realized by 
alternately switching the volume flow of the individual solutions on and off; b) Schematic of 
a staggered herringbone micromixer for chaotic advection at low Reynolds number. 
Staggered herringbone grooves on the bottom of the main channel are arranged in repeating 
sequences each containing several grooves. Perspective view on channel structures in the 
herringbone micromixer (inserted picture). 
 
A further possibility for increasing the efficiency of mixing is the use of multiphase flows, 
meaning that immiscible phases are admitted into a microchannel. Thereby small segments 
(plugs or droplets) are formed separated from each other by a more or less inert gaseous or 
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liquid phase (Figure 13a). Within these segments the contact surface between the solvent and 
anti-solvent can be increased by internal vortices. Such multiphase flow is also known as 
Taylor flow (Gupta et al., 2010). To establish Taylor flow mixing the solvent and the anti-
solvent are combined at an intersection point and the flow is subsequently segmented with a 
gas phase into individual plugs. Shear forces on the channel walls create relative backflows in 
a segmented liquid plug, which induce vortices symmetrical to the channel central axes. The 
mixing time can be controlled by the size of the segmented plugs, which determines the size 
of the precipitated nanoparticles (Erfle et al., 2019).  
 
A dramatic reduction of diffusion distances can also be achieved if droplets are formed with 
extremely small volumes on the order of nano- or femtoliters (Figure 13b). In some cases, to 
create such small droplets, the solvent and the antisolvent in a droplet can be transferred into 
a non-miscible medium (oil, for example) by flow focusing. The solutions within the droplet 
are subsequently mixed by diffusion (Günther and Jensen, 2006). As an alternative, the 
solvent can be injected as a droplet into the anti-solvent itself, which allows the solvent to 
diffuse from the droplet into the surrounding medium (Lorenz et al., 2018). The size of the 
nanoparticle is thereby determined by the amount of the dissolved active ingredient contained 




Figure 13. Schematic illustrations of two concepts of multiphase micromixers. A) Gas-liquid 
mixer (Taylor flow system), in which the solvent and anti-solvent are combined by flow-
focusing and an injected gas phase segments the flow; b) Droplet formation, in which the 
solvent stream is narrowed with the antisolvent sheath flow leading to flow focusing. The 
filament stream breaks off into individual droplets. A suitable choice of solvent and a 
stabilizer is a necessary condition for a stable droplet formation 
 
3.2.4. Flow rate ratio (FRR) 
Flow rate ratio (FRR) is the ratio of the drug/polymer solution (solvent-S) flow rate to the 
antisolvent (AS) flow rate. As was discussed previously in section 3.1, changing the flow rate 
ratio (S/AS) simultaneously changes more than one factor including the degree of 
supersaturation (shown in Figure 14), the total drug concentration that affects the collision 
rate and particle aggregation, the solvent content that affects the stability of the produced 
nanoparticles, and the efficiency of the mixing process by modulating the path-length for 




Figure 14. Schematic representation of the effect of the solvent anti-solvent ratio on the 
precipitation process (reprinted and modified with permission from (Nagy et al., 2019)). 
 
As illustrated in Figure 14, increasing the S-AS ratio while maintaining the same drug 
content in the binary mixture will induce a relatively low degree of supersaturation, and 
hence a low nucleation rate with a higher crystal growth rate and, ultimately, larger particles. 
At a low S-AS ratio, a high degree of supersaturation (where homogenous nucleation 
dominates over crystal growth) could be easily attained even with low solute concentrations 
(Ali et al., 2009; Kulkarni and Myerson, 2017; Su et al., 2007; Zhao et al., 2007). 
 
In the case of a flow focusing microchip that does not involve droplet formation (as shown in 
Figure 15), decreasing FRR makes the solvent stream sheathed by the surrounding 
antisolvent stream and decreases the path-length required for the drug molecule to diffuse 
from solvent to antisolvent stream which in turn reduces tmix as shown in Eq. 16. 
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                         Eq. 16 
 
where D is the diffusivity of the solvent, Wf is the width of the internal focused stream, W is 
the channel width, and R is the flow rate ratio. To the best of our knowledge, these factors 
have not been investigated independently in any reported literature.  
 
Figure 15. The effect of different FRR on the pathlength for diffusion within a flow focusing 
microchip. (reprinted with permission from (Lababidi et al., 2019)). 
 
Baby T. et al (Baby et al., 2017) have investigated the effect of using different FRR on the 
particle size of PLGA nanoparticles using PLGA and PEG with different molecular weights 
(namely, PLGA20K-PEG5K and PLGA55K-PEG5K). They found that increasing FRR from 0.1 
to 0.8 increased the particle size from 32.0 ± 0.6 nm to 62.6 ± 0.4 nm for PLGA20K-PEG5K. 
This effect was more pronounced for PLGA55K-PEG5K nanoparticles (the particle size 
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increased from 111.9 ± 0.4 to 141 ± 1 nm as the FRR was increased from 0.1 to 0.8). Similar 
observations were reported by Donno et al (Donno et al., 2017).  
 
3.2.5. Total flow rate (TFR) 
The TFR is the sum of the flow rates of both solvent and antisolvent solutions in the 
microchip. Through TFR, it is possible to predict the residence time of the drug molecule 
within the microchip. Assuming that the cross-sectional area is constant, a higher TFR 
shortens the residence time of the drug molecule (or nuclei) inside the chip, and therefore 
reduces the risk of nanoparticle aggregates building up in the channel and the subsequent 
clogging of the chip (Amoyav and Benny, 2018; Wang et al., 2010). 
 
During the preparation of hydrocortisone NPs in a microfluidic device, Ali et al (2009) 
observed that the particle size decreased from 289 nm to 80 nm by increasing the TFR from 
1ml/min to 3ml/min. Lababidi and co-workers observed a reduction in the mean diameter of 
PLGA NPs from 150 to 70 nm on increasing the TFR by increasing the flow rate of the 
external phase (keeping the FRR constant at 0.05) from 10 to 100µL/min (Lababidi et al., 
2019). Similar effects were reported in the manufacturing of PLGA NPs using acetonitrile as 
the solvent and Tris buffer at pH 7.4 as antisolvent, where it was noticed that increasing TFR 
from 5 to 15 mL/min led to a decrease in the mean particle diameter from about 380 to 125 
nm (E. Chiesa et al., 2018). 
 
A short residence time is favoured to produce small nanoparticles with a narrow particle size 
distribution as it lowers the possibility of heterogeneous nucleation resulting from contact 
between the supersaturated solution with the microchip walls. Furthermore, increasing the 
fluid flow speed inside the chip raises the Peclet number Pe (see Eq. 15) and hence increases 
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the relative contribution of advection versus diffusion to the mass transfer (Saad and 
Prud’Homme, 2016; Tao et al., 2019). 
 
4. Microfluidic application in preparation of drug/polymer nanoparticles 
4.1. The use of microfluidic systems to produce drug nanoparticles 
As previously mentioned, microfluidic systems have been used to produce drug 
nanosuspensions by nanoprecipitation method. In view of this application, we can categorize 
the used systems as mixers dominated either by diffusion or by turbulent mixing. Studies of 
drug particle nanosuspension production via diffusive micro-mixing have reported that the 
microchip path-length is too short to allow for sufficient mixing and the formation of stable 
precipitated particles (Aghajani et al., 2013; Ali et al., 2011, 2009; Zhao et al., 2007). Thus, 
the precipitation process in that case does not only depend on microchip geometry, FRR and 
TFR, but also depends on the vessel that receives the suspension after leaving the microchip. 
A mixing microdevice combined with sonication was reported by Ali and co-workers (Ali et 
al., 2011, 2009). The microchip outlet was subjected to dilution with stirring and exposed to 
sonication (unspecified intensity or time). Therefore, the influences of different microchip 
parameters in that case were masked by high-energy process (sonication) and by further 
dilution with mixing. Therefore often the properties of the particles generated using 
conventional flow-focusing droplet junction microchip may not be significantly different 
from the ones generated by conventional nanoprecipitation. However, with the advancement 
in chip design, microfluidics method can allow rapid diffusion and induce secondary flows 
like Taylor vortices or Dean vortices which can accelerate the mixing enormously (Capretto 




4.2. Bulk methods compared to microfluidic platforms for polymeric nanoparticles 
fabrication   
Microfluidic devices have been used in the literature to produce small nanoparticles with 
narrow size distribution explained by the efficient rapid mixing achieved by manipulating the 
mixing of the fluids in micro-channels (Karnik et al., 2008; Bally et al., 2012; Miladi et al., 
2016). The polymer PLGA has been widely used to fabricate tuneable biodegradable 
nanoparticles in microfluidic devices. Xu and co-workers used a microfluidic flow-focusing 
method to manufacture doxorubicin- or tamoxifen-loaded PLGA nanoparticles (Xu et al., 
2017). By changing the flow rate ratio and the polymer concentration they were able to 
precisely control the size of the PLGA nanoparticles (Xu et al., 2017). However, PLGA 
nanoparticles prepared using bulk nanoprecipitation methods can also be precisely controlled 
by tuning the processing parameters such as the polymer concentration or the solvent/anti-
solvent volume ratio (Wei Huang and Chenming Zhang, 2017).  
 
Karnik and co-workers investigated the use of the microfluidics to fabricate smaller PLGA-
PEG nanoparticles compared to the bulk conventional methods (Bally et al., 2012; Miladi et 
al., 2016). The study reported an average particle size of 24 nm and 31 nm for the 
microfluidic nanoparticles and the conventional nanoparticles, respectively (Karnik et al., 
2008). However, it’s important to mention that ultra-small nanoparticles of 15 nm were 
fabricated by micropipette and shaking using the conventional nanoprecipitation technique 
(Reisch et al., 2015). These small nanoparticles were achieved by controlling the number of 
the charged group per polymer chain as one or two charged groups were found to 
significantly reduce the size of the nanoparticles (Reisch et al., 2015). This proves that when 
the processing parameters are precisely controlled, small nanoparticles can be achieved not 
only within microfluidic devices via enhanced mixing but also using conventional 
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nanoprecipitation. But, in comparing the relative merits of the two approaches, it is important 
to consider carefully the functionality improvements (such as enhanced solubility) that are 
gained by size reduction in microfluidic devices. Such improvements might also be realised 
using bulk precipitation methods, which have the advantage of a substantially higher 
throughput rate and are easier to scale-up. 
 
4.3 Truth and myth: Limitations of microfluidics application in the production of 
nanoparticles 
4.3.1 Productivity and scaling up 
According to the published data regarding the solute (drug/polymer) concentration used in 
microfluidic systems, it is clear that the production rate of the drug/polymeric nanoparticles is 
limited due to the microfluidic system dimensions and the used flow rates in comparison to 
conventional bulk mixing methods. For instance, Karnik and co-workers reported that the 
yield of the PLGA nanoparticles produced by a T-shaped hydrodynamic flow-focusing chip 
was 0.02376-0.792 g/day (Karnik et al., 2008). For drug nanosuspensions, using a Y-shaped 
microchip achieved the production of hydrocortisone nanosuspension at a throughput rate of 
18 g/day (Ali et al., 2011). More examples and their nanoparticle production can be found in 
a previously published review (Ding et al., 2016). 
 
The throughput can be increased by either raising the solute concentration (but not so much 
as to increase the size of the NPs) or increasing the TFR. Confined impinging jets mixers 
(CIJMs) and multi-inlet vortex mixers (MIVMs) have a much higher production rate (up to 
864 g/day) than most other conventional microfluidic chips. However, increasing the flow 
rate into the range around 100 ml/min means that the channels must be able to tolerate and 
withstand the pressure (such as steel microchips) (Saad and Prud’Homme, 2016; Tao et al., 
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2019). In these systems, the Peclet number Pe (Eq. 15) is high and the mixing will be 
dominated by advection. 
 
Production parallelization is another approach to increase the productivity (Amoyav and 
Benny, 2018). Kang and co-workers were the first to report the manufacture of a parallel line-
microchip to produce polymeric nanoparticles. They used parallel mixing lines between water 
(the anti-solvent) and the polymer solution in a 100 outlet channel to increase the TFR to 6 
ml/min using a PDMS microchip (Kang et al., 2013). A parallel 3D hydrodynamic flow-
focusing chip made of PDMS (Figure 16), and designed by Lim and the co-workers, was 
found to be efficient for the production of 13-150 nm PLGA-PEG nanoparticles. It had an 
enhanced throughput of 25 mg of polymeric nanoparticles in 20 min compared to 5 hours 
when using single layer microchips (Lim et al., 2014a; Rhee et al., 2011). Although levelling 
up microfluidics into the industrial scale remains a challenge (even after parallelization), 
there are nonetheless promising developments in using microchips to increase nanoparticle 
production rates. 
 
Figure 16. An example of a parallel 3D hydrodynamic flow-focusing microchip (reprinted 
with permission from (Lim et al., 2014a)). 
 
4.3.2. Chip clogging 
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Clogging of microchips is another problem that makes it difficult to maintain a continuous 
process flow. Increasing the solute concentration or using relatively low TFR leads to 
precipitation in the channel and subsequent particle growth inside the chip. Eventually this 
results in the complete clogging of the microchannel. Surface interactions such as the 
aggregation of polymeric nanoparticles (e.g. PLGA NPs) on the inner hydrophobic surfaces 
of the PDMS chips is another possible cause of chips clogging (Rhee et al., 2011). To 
mitigate clogging 3D flow focusing microchips have been designed (Figure 17) to keep the 
precipitation of the nanoparticles away from the walls of the microchannels and thus allow 
the flow to be continued without any disruption or clogging. Different channel/microcapillary 
designs have been tested for this purpose and several promising studies reported the 
prevention of clogging and maintenance of flow continuity (Lim et al., 2014a, 2014b; Liu et 
al., 2017; Lorenz et al., 2018; Rhee et al., 2011). 
 
 
Figure 17. 3D hydrodynamic flow-focusing to prevent microchip clogging (reprinted with 





Using precipitation as the mode of particle formation, microfluidic devices with miniature-
machined channels can achieve more precise control of the mixing of the fluid phases than 
conventional bulk mixing methods. In terms of drug-loaded nanoparticles, microfluidic 
methods allow tuneability to the size and drug loading which can often be difficult to achieve 
by conventional preparation methods. Most microfluidic methods still face challenges in 
scale-up to achieve the same throughput as conventional methods for large batch production, 
although there are promising reports of improvements, In practice, the feasibility of using 
microfluidics to generate particles, and to control the quality of the particles, is highly 
dependent on the materials used as well as the design of the microfluidic channel and the 
surface chemistry that affects the flow and mixing of the fluid phases. Although material and 
surface chemistry aspects have been well studied, there is still no systematic analysis of the 
correlation between particle properties and the microfluidic device design. More research is 
are needed before the widespread adoption of this processing technique for research and 
industrial applications can be realised. 
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